NZ750450B2 - Use of probiotics in the treatment and/or prevention of atopic dermatitis - Google Patents
Use of probiotics in the treatment and/or prevention of atopic dermatitisInfo
- Publication number
- NZ750450B2 NZ750450B2 NZ750450A NZ75045017A NZ750450B2 NZ 750450 B2 NZ750450 B2 NZ 750450B2 NZ 750450 A NZ750450 A NZ 750450A NZ 75045017 A NZ75045017 A NZ 75045017A NZ 750450 B2 NZ750450 B2 NZ 750450B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition according
- concentration
- probiotic
- lactis
- longum
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
The present invention is intended for the use of a probiotic composition comprising Bifidobacterium animalis subsp. lactis (B. lactis), Bifidobacterium longum, and Lactobacillus casei, particularly the strains Lactobacillus casei CECT 8145, B. lactis CECT 7347 and/or B. longum CECT 9104, in the treatment and/or prevention of atopic dermatitis.
Claims (14)
1. A probiotic composition comprising Bifidobacterium animalis subsp. lactis (B. lactis), Bifidobacterium longum and Lactobacillus casei, wherein B. lactis is B. lactis CECT 8145, B. longum is B. longum CECT 7347 and L. casei is L. casei CECT 9104.
2. Probiotic ition according to claim 1 , wherein the probiotic ition is a pharmaceutical ition or a nutritional composition.
3. The probiotic composition according to claim 2, n the ceutical composition ses a pharmaceutically acceptable carrier and/or an excipient.
4. The probiotic composition ing to claim 2 or 3, wherein the pharmaceutical composition is formulated for administration in liquid form or in solid form.
5. The probiotic composition according to claim 4, wherein the solid formulation is selected from the group consisting of tablets, lozenges, , chewable tablets, chewing gum, capsules, sachets, powders, granules, coated particles or coated tablets, tablets and gastro-resistant tablets and capsules and dispersible strips and/or films.
6. The probiotic composition according to claim 4, wherein the liquid formulation is selected from the group consisting of oral solutions, suspensions, emulsions and syrups.
7. The probiotic composition according to claim 2, wherein the nutritional composition is a food or a ional supplement.
8. The probiotic composition according to claim 7, wherein the food is selected from the group consisting of fruit or vegetable juices, ice cream, infant formula, milk, yogurt, cheese, fermented milk, milk powder, cereals, baked goods, milk-based products, meat products and beverages.
9. The probiotic composition according to any one of claims 1 to 8, wherein the composition further comprises a microorganism selected from the group consisting of Lactobacillus sp., Streptococcus sp., Bifidobacterium sp., Saccharomyces sp., Kluyveromyces sp. and combinations thereof.
10. The probiotic composition according to any one of claims 1 to 9, wherein the total concentration of microorganisms of the strains B. , L. casei and B. longum in the composition is between 103 and 1012 cfu, ably 109 cfu.
11. The tic composition according to any one of claims 1 to 10, wherein B. longum concentration is at least between 30% and 40% with respect to the total concentration of microorganisms present in the composition; and/or B. lactis concentration is at least between 30% and 40% with respect to the total tration of microorganisms; and/or L. casei concentration is at least between 25 and 35% with respect to the total concentration of microorganisms.
12. The tic ition according to claim 11, wherein B. longum concentration is 35% with respect to the total concentration of microorganisms present in the composition; B. lactis concentration is 35% with respect to the total concentration of microorganisms, and/or L. casei concentration is 30% with respect to the total concentration of microorganisms.
13. Use of a probiotic composition according to any one of claims 1 to 12 in the cture of a medicament.
14. Use of a probiotic composition according to any one of claims 1 to 12 in the manufacture of a medicament for use in the treatment and / or prevention of atopic dermatitis. 7339.25 mlngEuEm. nImQZEmEm 839w?” mzszEnwlmlr 3331...? 2:32.. .3:me 5%. 9H4, 3.63:2:meth ® 65> ® © 0 umc?axa ® comthoO $0.0m. ?w M M ?
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382342.0A EP3272396A1 (en) | 2016-07-18 | 2016-07-18 | Use of probiotics in the treatment and/or prevention of atopic dermatitis |
| PCT/EP2017/068131 WO2018015388A1 (en) | 2016-07-18 | 2017-07-18 | Use of probiotics in the treatment and/or prevention of atopic dermatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ750450A NZ750450A (en) | 2025-07-25 |
| NZ750450B2 true NZ750450B2 (en) | 2025-10-29 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018136939A (en) | APPLICATION OF PROBIOTICS FOR THE TREATMENT AND / OR PREVENTION OF PSORIASIS | |
| RU2019104462A (en) | APPLICATION OF PROBIOTICS IN THE TREATMENT AND / OR PREVENTION OF ATOPIC DERMATITIS | |
| RU2004128078A (en) | LIGHT PROTECTED FOR ORAL RECEPTION COMPOSITION FOR SKIN | |
| US8877179B2 (en) | Frozen confections containing probiotic micro-organisms | |
| EP2990045B1 (en) | Bifidobacterium animalis subsp. lactis for use in decreasing abdominal pain in a postmenopausal woman | |
| CN103180432B (en) | Prepare the method for shelf-stable probiotic food | |
| KR101487210B1 (en) | Anti-allergic composition | |
| SI3048165T1 (en) | Novel strain of bifidobacterium animalis subsp. lactis cect 8145 and use thereof for the treatment and/or prevention of excess weight and obesity and associated diseases | |
| CA2477144A1 (en) | Orally administrable composition for the photoprotection of the skin | |
| Otles et al. | Probiotics and health | |
| JP2018520677A5 (en) | ||
| CN109715181B (en) | Bacteria | |
| RU2013126609A (en) | EXTRUDED NON-REPLICATING PROBIOTIC MICRO-ORGANISMS AND THEIR HEALTH BENEFITS | |
| WO2021256476A1 (en) | Method for improving resistance of lactic acid bacteria to gastric juices/bile | |
| Lokhande et al. | A systematic study of probiotics-an update review | |
| HRP20250886T1 (en) | POSTBIOTICS PREPARATIONS CONTAINING B. LONGUM CECT-7347 AND L. RHAMNOSUS CECT-8361 AND THEIR THERAPEUTIC USE | |
| JP2024546663A5 (en) | ||
| Stabnikov et al. | Recent advances in the study of the properties and applications of lactic acid bacteria | |
| JP5238166B2 (en) | Interleukin 12 production inhibitor | |
| He et al. | Probiotic properties of lactic acid bacteria isolated from Tibetan kefir grain. | |
| JP2025026756A (en) | Bifidobacteria growth promoter | |
| NZ750450B2 (en) | Use of probiotics in the treatment and/or prevention of atopic dermatitis | |
| NZ747129B2 (en) | Use of probiotics in the treatment and/or prevention of psoriasis | |
| JP5980785B2 (en) | New bifidobacteria and their use | |
| Ortega | Comparative viability of spray dried Lactobacilli affected by different protective agents and storage conditions |